L3VLUP
ProSign in

ALKS · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALKSLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALKS
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterALKSLLY
Q3 202010 holders, $1.0bn33 holders, $14.1bn
Q4 202013 holders, $1.2bn29 holders, $17.3bn
Q1 202112 holders, $1.1bn24 holders, $23.0bn
Q2 202113 holders, $1.3bn24 holders, $27.8bn
Q3 202111 holders, $1.4bn31 holders, $29.9bn
Q4 20219 holders, $1.1bn31 holders, $34.7bn
Q1 202210 holders, $1.2bn24 holders, $35.3bn
Q2 202212 holders, $903m33 holders, $42.7bn
Q3 202210 holders, $547m31 holders, $43.4bn
Q4 202212 holders, $831m31 holders, $46.6bn
Q1 202312 holders, $708m33 holders, $44.3bn
Q2 202312 holders, $703m37 holders, $59.6bn
Q3 202312 holders, $778m44 holders, $67.6bn
Q4 20237 holders, $754m45 holders, $73.6bn
Q1 20248 holders, $927m41 holders, $95.3bn
Q2 20247 holders, $823m43 holders, $110bn
Q3 20248 holders, $955m45 holders, $107bn
Q4 20247 holders, $801m46 holders, $93.9bn
Q1 20259 holders, $813m42 holders, $98.4bn
Q2 20259 holders, $642m43 holders, $93.2bn
Q3 202510 holders, $703m39 holders, $86.7bn
Q4 20259 holders, $566m41 holders, $123bn
Q1 202610 holders, $436m39 holders, $106bn
Q2 20269 holders, $1.2bn44 holders, $132bn
ALKS

Alkermes PLC

Holders
9
Reported value
$813m
Buyers
7
Sellers
2

Breadth +5 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
42
Reported value
$98.4bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALKS (3)

ExodusPoint Capital Management LP, Farallon Capital Management LLC, PDT Partners LLC

Only LLY (36)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Egerton Capital UK LLP, Eisler Capital Management Ltd, Element Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Lone Pine Capital LLC, Man Group PLC, Marshall Wace LLP, MFS Investment Management, and 11 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →